Baxter International acquires Recothrom and Preveleak Surgical Sealant from Mallinckrodt.

Baxter International Inc. announced an agreement to acquire two hemostat and sealant products from Mallinckrodt plc : Recothrom Thrombin topical (Recombinant), the first and only stand-alone recombinant thrombin, and Preveleak Surgical Sealant, which is used in vascular reconstruction.

Thrombin is a proven blood coagulation agent - used on its own or in combination with other hemostats - that has been estimated to be used in more than one million patients per year in the United States to help surgeons address intraoperative bleeding . Recothrom is a thrombin-based product indicated as an aid to hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques is ineffective or impractical in adults and pediatric populations greater than or equal to one month of age. As the only topical hemostat from recombinant DNA origin approved in the United States and Canada , Recothrom can be used in pediatric and adult patients with or without antibodies to bovine-derived thrombin.

The acquisition also includes Preveleak, a surgical sealant designed to seal suture holes formed during surgical repair of the circulatory system and to reinforce sutured connections between blood vessel. Preveleak is approved in the United States and European Union .